PSY33 Total costs of care in the 90 days following emergency department visits for patients taking exclusively class-II or class-III short-acting opioids  by Ernst, F.R. et al.
A116 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
PSY31  
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OBJECTIVES: Transfusions are linked to adverse outcomes such as mortality, 
post-operative morbidity and increased costs. Patients who have undergone 
open spine surgery can experience high volume of blood loss and require 
transfusions due to the extensive muscle dissection associated with  
the procedure. Recently, there has been a focus on minimally invasive spine 
surgery techniques (MIS) that can minimize the exposure of tissue during spine 
surgery, which has resulted in the reduction of blood loss and related 
transfusions. METHODS: This retrospective study utilized the Premier 
Perspective® database to compare costs of transfusion between patients who 
underwent 1-2 level MIS posterior lumbar interbody fusion (n=727) and  
open spine fusion (n=727) matched based on age and gender. A regression model 
was used to assess the impact of factors that affected the likelihood  
of transfusion. RESULTS: Patients who underwent MIS surgery had significantly 
fewer transfusions of perioperative autologous blood (1.8% vs. 6.2%), packed cells 
(5% vs. 10%) and platelets (0% vs. 0.6%) when compared to open fusion (p<0.05). 
The per patient transfusion cost for MIS was $252 lower than that of the  
open surgery. Per patient costs of antifibrinolytics, ESAs/hematinics and blood 
drainage were statistically lower for MIS fusion when compared to open fusion 
(p<0.05). The factors that were identified for the transfusion prediction model 
were surgery type, Charlson index, implanted screws, type/region of hospital, 
and type of insurance. The model showed that use of MIS fusion contributed 
most to the reduction in likelihood of transfusion when compared to the  
other variables (OR=0.441, p<0.0001). CONCLUSIONS: MIS fusion patients require 
fewer transfusions, thus resulting in lower mean transfusion costs  
when compared to open fusion patients. MIS fusion patients are less likely  
to receive a transfusion when compared to open fusion patients. A limitation 
was that pre-op Hct was excluded as a model variable, due to unavailability of 
data.  
 
PSY32  
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OBJECTIVES: To estimate the economic consequences of changes in disease 
activity on HRU and costs. METHODS: An observational cohort study of SLE 
patients who received care in a regional integrated health delivery system from 
January 2004 through March 2011 was conducted using medical and hospital 
electronic health records, medical chart review, and health plan claims. Eligible 
patients were ≥18 years old, had ≥1 rheumatologist-confirmed SLE diagnosis and 
≥1 eligible rheumatology-encounters, i.e., SLE visits in rheumatology, nephrology 
or emergency department. Patients were continuously enrolled ≥90 days before 
and after the encounters. Charts were manually reviewed to estimate SLEDAI 
scores (SS). Average unit costs of each medical procedure, facility use, and per-
unit prescription were estimated from a payer perspective from a third-party 
managed care claims database. HRU and costs were calculated for the 30-day 
period surrounding every SS date (10 before and 19 days after) and the entire 
period of health plan enrolment. Relationships between HRU/costs and SS were 
estimated using mixed-effect models. RESULTS: A total of 178 SLE patients were 
included; mean age was 50.6 years, 91% female, and 95.5% Caucasians. Patients 
had a total of 1343 encounters with valid SS (average observation period: 1,035 
days). SLE patients incurred average annual costs of $18,839. Reductions of SS 
were significantly associated with reductions in HRU and costs. SS reductions of 
4 points were associated with 10% and 14% reductions of HRU and costs over a 
30-day period; reductions of 8 points were associated with 19% and 26% 
reductions of HRU and cost; and reductions of 10 points were associated with 
23% and 31% reductions of HRU and cost. Annualized, these changes of SS scores 
are associated with changes of $5579 (SS change from 10 - 0), $4624 (10-2), and 
$2485 (10-6), respectively. CONCLUSIONS: Reductions in disease activity were 
associated with substantial reductions of HRU and costs.  
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OBJECTIVES: Patients using opioids chronically may be especially costly to 
Accountable Care Organizations (ACOs) and their hospitals, partly because 
medication portfolios of these patients may be suboptimal. To better understand 
these patients, we leveraged hospital and claims data for patient level 
continuum of care analyses, focusing on chronically prescribed short-acting 
opioids without baseline long-acting opioids. METHODS: Using linked data from 
the Premier hospital database and Optum commercial claims, we selected 
patients chronically taking opioid pain medications who presented to an 
emergency department (ED) from 2006-2010. We focused on the subset who 
exclusively took short-acting opioid analgesics, comparing those using Schedule 
C-II opioids to patients using only C-III opioids. We analyzed total inpatient and 
outpatient costs at intervals within the 90-day period following the ED visit. We 
used Medicare reimbursement for medical services and patient copays for 
medications. Bootstrap analyses with 1000 replications were performed 
adjusting for primary diagnoses plus 28 comorbid conditions. RESULTS: We 
identified 5,240 chronic opioid patients receiving exclusively short-acting C-II 
(SAC-2) opioids and 1,587 using only short-acting C-III (SAC-3) opioids. Within 72 
hours of the ED visit, adjusted and unadjusted costs were higher for SAC-2 
versus SAC-3 patients ($2,411±4,023 vs. $2,354±3,461; p<0.05). At 30, 45, 60, and 90 
days, respectively, mean costs were higher for SAC-2 patients compared to SAC-
3 patients ($5,694±9,201 vs. $4,561±8,069, $7,244±11,580 vs. $5,500±9,640, 
$8,678±13,601 vs. $6,369±11,120, and $11,571±17,400 vs. $7,938±13,736; all p<0.05). 
Adjusted mean differences were $48, $731*, $1,152*, $1,586*, and $2,457* (*p<0.05) 
at 72 hours, 30 days, 45, 60, and 90 days. CONCLUSIONS: Total costs of care were 
higher for patients receiving only SAC-2 opioid analgesics than for patients 
receiving only SAC-3 opioids. This was consistent at all analyzed intervals of 
time within the 90 days following an ED visit. Further analyses of patients having 
other opioid medication portfolios may be warranted.  
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OBJECTIVES: The World Health Organization defines obesity as BMI≥30 and 
overweight as BMI≥25. While previous studies have shown these are associated 
with higher medical and non-medical costs, less is known about the continuous 
relationship between unit changes in BMI and cost. This study measures the 
impact of BMI as a continuous variable on several employee-related cost 
outcomes. METHODS: Using a retrospective database from 5 large employers 
throughout the US, employees’ BMI values from 2003-2011 health risk appraisals 
were used as continuous variables in generalized additive regression models. All 
employees were required to have ≥12 months of health coverage post-index (first 
BMI measurement). Employees with pregnancy-related medical claims and those 
with BMI<18 or >47 were excluded. Medical and drug costs, sick leave (SL), short- 
and long-term disability (STD; LTD), workers’ compensation (WC) costs, work 
absence days, and Health Productivity Questionnaire responses were measured 
12 months post-index. Turnover was measured 12-18 months post-index. Models 
controlled for age, gender, marital status, race, salary, zip-code region, and index 
year. RESULTS: The study included 72,778 eligible employees; 32.4% were female. 
Average BMI, age and annual salary, were 27.3, 39.7 years and $81,114, 
respectively. For each unit increase in BMI, significant changes (each P<0.0001) in 
annual costs (medical [$97 per additional unit of BMI (at the mean)], drug [$27], 
SL [$14], STD [$8], LTD [-$1], WC [$4]) and absence days (SL [0.072 days per 
additional unit of BMI (at the mean)], STD [0.018], LTD [-0.002], WC [0.013]) were 
found. Self-reported productivity also changed significantly (-0.0065 units per 
unit increase in BMI, P=0.0003). Turnover was non-significantly lower for higher 
levels of BMI. CONCLUSIONS: Employees with higher BMI levels are associated 
with significantly more costs, more absence from work, and lower self-reported 
productivity. Given their high prevalence, overweight and obesity represent a 
significant economic burden for US employers.  
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OBJECTIVES: Psoriasis is a chronic, inflammatory and autoimmune disease that 
occurs in the skin and causes flaking, swollen and pain. In Colombia there are  
no official reports on the disease burden of psoriasis. The aim of this study was 
to estimate the prevalence of psoriasis in Colombians (children and adults) and 
its associated costs in the private and public settings. METHODS: A meta-
analysis was conducted with literature found through a systematic review in 
electronic databases (Pubmed, Health Star, PsycINFO, Embase, Science Direct, 
OVID, Cochrane Library Database, INBIOMED and LILACS) and informally 
published written material to extract data regarding epidemiological and risk 
factors about psoriasis in Colombia. Twelve papers were included in the meta-
analysis. The information was validated through a panel of eight local experts. 
Institutional costs (taken from 7 private and 10 public health care centers  
in Bogota, Colombia) were used to estimate direct medical costs, complication 
resource use and treatment schedules were given by experts. Indirect costs were 
calculated considering disability length (labor days lost) generated by  
the disease. Costs are expressed in 2012 USD. RESULTS: The prevalence of 
psoriasis within the Colombian population estimated for 2012 was 2.0% (0.0062-
0.0340) (n=959,971). The most common presentation of psoriasis was: plaque 
(64.29%), followed by guttate (12.86%) and erythrodermic (2%). Most risk factors 
identified for psoriasis were smoking (40.71%); alcohol intake (29.29%) and 
medication use (23.57%). Total annual costs per patient (direct + indirect costs) 
associated with psoriasis treatment were: US$12,594.65 for private practice  
and US$10,894.92 for the public scenario. CONCLUSIONS: Psoriasis prevalence  
in Colombia is similar to those reported in latinamerican countries (1.7% – 2.2%). 
From a societal perspective, psoriasis represents a major economic burden  
for the local health system due to prevalence and cost per patient/year. Total 
annual costs per patient were US$1,699.73 higher in private than in the public 
scenario.  
